Literature DB >> 15944014

Mechanisms of antinociception of spinal galanin: how does galanin inhibit spinal sensitization?

X-Y Hua1, K F Salgado, G Gu, B Fitzsimmons, I Kondo, T Bartfai, T L Yaksh.   

Abstract

Galanin by a spinal action has been shown to have an antihyperalgesic action. Thus, in rats with lumbar intrathecal (IT) catheters, the thermal hyperalgesia evoked by carrageenan paw injection was blocked by IT delivery of galanin(1-29) (Gal(1-29)) and galanin(2-11) (Gal(2-11)) with the rank order of activity being Gal(1-29)>Gal(2-11). We sought to determine whether this spinal action reflects an effect upon afferent transmitter release, e.g., substance P (SP), and/or on secondary neurons, e.g., signaling postsynaptic to neurokinin 1 (NK1) receptor activation. To address the question on afferent release, we investigated the effect of IT administration of galanin on tissue injury-induced spinal NK1 internalization (an indicator of SP release). Noxious stimulation (paw compression) produced an increase in NK1 internalization in dorsal horn lamina I. IT pretreatment of rats with Gal(1-29) and Gal(2-11) significantly attenuated the evoked NK1 internalization, with the rank order of activity being Gal(1-29)>Gal(2-11)>saline. To address the question of postsynaptic action, we examined the effects of IT galanin upon IT SP-induced thermal hyperalgesia and spinal PGE2 release. Application of SP (30 nmol) directly to spinal cord led to a decrease in thermal thresholds and a profound increase in PGE(2) concentration in spinal dialysates. Both phenomena were reversed by Gal(1-29) and Gal(2-11) (10nmol, IT). These findings suggest that the antihyperalgesic effect of spinal galanin is due to its action on sites both presynaptic (inhibition of SP release) and postsynaptic (blockade of SP-evoked hyperalgesia and PGE2 production) to the primary afferents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944014     DOI: 10.1016/j.npep.2004.12.024

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  5 in total

1.  Expression of galanin and galanin receptor mRNA in skin during the formation of granulation tissue.

Authors:  Hiroyuki Yamamoto; Takeo Arai; Shinta Ben; Kazuaki Iguchi; Minoru Hoshino
Journal:  Endocrine       Date:  2011-09-06       Impact factor: 3.633

2.  Analgesic properties of a peripherally acting and GalR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models.

Authors:  Cameron S Metcalf; Brian D Klein; Daniel R McDougle; Liuyin Zhang; Misty D Smith; Grzegorz Bulaj; H Steve White
Journal:  J Pharmacol Exp Ther       Date:  2014-10-27       Impact factor: 4.030

3.  Effects of exogenous galanin on neuropathic pain state and change of galanin and its receptors in DRG and SDH after sciatic nerve-pinch injury in rat.

Authors:  Xiaofeng Xu; Xiangdong Yang; Ping Zhang; Xiuying Chen; Huaxiang Liu; Zhenzhong Li
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

4.  Galanin and its receptor system promote the repair of injured sciatic nerves in diabetic rats.

Authors:  Xiao-Feng Xu; Dan-Dan Zhang; Jin-Chi Liao; Li Xiao; Qing Wang; Wei Qiu
Journal:  Neural Regen Res       Date:  2016-09       Impact factor: 5.135

5.  Opioid analgesia and the somatosensory memory of neonatal surgical injury in the adult rat.

Authors:  O Moriarty; L Harrington; S Beggs; S M Walker
Journal:  Br J Anaesth       Date:  2018-02-01       Impact factor: 9.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.